DelveInsight’s ‘Catheter-Related Bloodstream Infection (CRBSI) -Market Insights, Epidemiology, and Market Forecast-2030’ report delivers an in-depth understanding of the catheter-related bloodstream infection, historical and forecasted epidemiology as well as the catheter-related bloodstream infection market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), Japan, APAC (China, India, Taiwan, South Korea, and Australia), LATAM (Brazil, Mexico, Argentina, and Colombia), Middle East (Saudi Arabia and the United Arab Emirates), and Russia.
• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan
• APAC (China, India, Taiwan, South Korea, and Australia)
• LATAM (Brazil, Mexico, Argentina, and Colombia)
• Middle East (Saudi Arabia and the United Arab Emirates)
• Russia
Catheter-Related Bloodstream Infection Overview
Catheter-related bloodstream infection also known as catheter-related sepsis, defined as the presence of bacteremia originating from a catheter insertion. Antibiotics such as antibacterial and antifungal are used for the treatment of the disease. Antibiotic lock therapy is considered as adjunctive therapy in the treatment of CRBSI when catheter removal is not a favorable option. The current treatment options are used as off-label therapies and only a few non-antibiotic lock solutions are approved in Europe.
The diagnosis of catheter-related bloodstream infection remains a major challenge. Fever and chills that are often associated with catheter-related bloodstream infections are not specific. Furthermore, local catheter inflammation and phlebitis could exist in the absence of catheter-related bloodstream infection or even a local infection, as has been reported with peripherally inserted central catheters.
The ‘gold standard’ for the diagnosis of catheter-related bloodstream infection is the combination of positive blood culture with the same organism isolated from the catheter. However, a major diagnostic problem is that traditional methods of catheter culture necessitate the removal of the central venous catheters (CVC), whereby the line tip is either rolled on an agar plate or placed in a nutrient broth.
It covers the details of conventional and current medical therapies available in the catheter-related bloodstream infection market for the treatment of the condition. It also provides the treatment guidelines and algorithms of the United States and Spain.
The DelveInsight’s catheter-related bloodstream infection market report gives a thorough understanding of catheter-related bloodstream infection by including details such as disease definition, causes, risk factors, pathogenesis, and diagnosis.
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Incident Population of Catheter-Related Bloodstream Infection Total Diagnosed Incident Population of Catheter-Related Bloodstream Infection, and Diagnosed Incidence of Catheter-Related Bloodstream Infection by Causative Pathogens scenario of catheter-related bloodstream infection in the global market covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom), Japan, APAC (China, India, Taiwan, South Korea, and Australia), LATAM (Brazil, Mexico, Argentina, and Colombia), Middle East (Saudi Arabia and the United Arab Emirates), and Russia from 2017 to 2030.
This section provides glimpses of the catheter-related bloodstream infection epidemiology in the global market.
The drug chapter segment of the catheter-related bloodstream infection report encloses the detailed analysis of catheter-related bloodstream infection marketed drugs and late stage (phase III) pipeline drugs. It also helps to understand the catheter-related bloodstream infection clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
Neutrolin: CorMedix
Neutrolin (CRMD003), is a non-antibiotic, anti-infective developed by CorMedix as a preventative solution to decrease the threat of infection and blood clots (thrombosis), thereby keeping CVCs operating safely and efficiently. It is a catheter lock solution for the prevention of catheter-related bloodstream infection and maintenance of catheter patency in hemodialysis patients.
Products detail in the report…
Taurosept: Geistlich Pharma
TauroSept is an antimicrobial solution (lock solution) developed by Geistlich Pharma for the prevention of catheter-related infection and is intended for installation in intravenous catheters between treatments to lock the catheter. It mainly contains antibacterial chemotherapeutic agent taurolidine.
Products detail in the report…
Daptomycin
Daptomycin is a cyclic lipopeptide parenteral antibiotic derived from Streptomyces roseosporus. It exhibits rapid concentration-dependent bactericidal activity against Gram-positive pathogens such as methicillin-resistant Staphylococcus aureus (MRSA).
Products detail in the report…
Vancomycin
Vancomycin is a tricyclic glycopeptide antibiotic originally derived from the organism Streptococcus orientalis. Vancomycin is used for the treatment and prevention of various bacterial infection caused by Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA).
Products detail in the report…
Mino-Lok: Citius Pharmaceuticals
Mino-Lok is an antibiotic lock solution used to treat patients with central line-associated bloodstream infection/catheter-related bloodstream infection. It is a combination of minocycline, edetate (disodium EDTA), and ethyl alcohol, all of which act synergistically to break down bacterial biofilms, eradicate the bacteria, provide anti-clotting properties to maintain patency in CVCs, and salvage the indwelling catheter.
Products detail in the report…
The catheter-related bloodstream infection market outlook of the report helps to build a detailed comprehension of the historic, current and forecasted catheter-related bloodstream infection market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers, and demand of better technology.
This segment gives a thorough detail of catheter-related bloodstream infection market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, catheter-related bloodstream infection global market is expected to change in the study period 2017–2030.
This section includes a glimpse of the catheter-related bloodstream infection global market. The market size of CRBSI in the Global market was USD 1,237.38 million in 2017.
The United States Market Outlook
This section provides the total catheter-related bloodstream infection market size and market size by therapies in the United States.
Among the Global Market, the United States had the highest market size of CRBSI in 2017, which accounts for approximately 55% of the total market. The growth of market size for CRBSI is attributed to currently prescribed treatment regimens as well as emerging therapies. The market size for CRBSI was found to be USD 381.5 million in 2017.
EU-5 Market Outlook
The total catheter-related bloodstream infection market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.
Japan Market Outlook
The total catheter-related bloodstream infection market size and market size by therapies in Japan are provided.
APAC Market Outlook
The total catheter-related bloodstream infection market size and market size by therapies in China, India, Taiwan, South Korea, and Australia are provided in this section.
India accounts for approximately 34.7% of the total APAC market of CRBSI. DelveInsight’s estimations suggest that the overall market size of CRBSI will increase at a moderate pace with USD 178.72 million in 2017 to USD 189.32 million in 2022. This is due to the dependency on the market size of CRBSI on supportive treatment regimens.
LATAM Market Outlook
The total catheter-related bloodstream infection market size and market size by therapies in Brazil, Mexico, Argentina, and Colombia are provided.
Argentina accounts for 13.7% of the total LATAM market of CRBSI. DelveInsight’s estimates suggest that the overall market size of CRBSI will grow with USD 8.59 million in 2017 to USD 9.23 million in 2022. This is attributed to the dependency on the market size of CRBSI on supportive therapies for CRBSI.
Middle East Market Outlook
The total catheter-related bloodstream infection market size and market size by therapies in Saudi Arabia and the United Arab Emirates are provided in this section.
Russia Market Outlook
The total catheter-related bloodstream infection market size and market size by therapies in Russia are provided in this section.
This section focusses on the rate of uptake of the potential drugs recently launched in the catheter-related bloodstream infection market or expected to get launched in the market during the study period 2017–2030. The analysis covers catheter-related bloodstream infection market uptake by drugs; patient uptake by therapies; and sales of each drug.
The report provides insights into different therapeutic candidates in phase II, and phase III stage. It also analyzes key players involved in developing targeted therapeutics.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition, and merger, licensing and patent details for catheter-related bloodstream infection emerging therapies.
Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In the report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.
KOL- Views
To keep up with current market trends, we take KOLs and SME’s opinion working in catheter-related bloodstream infection domains through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or catheter-related bloodstream infection market trends. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.
Competitive Intelligence Analysis
We perform competitively and market Intelligence analysis of the catheter-related bloodstream infection market by using various competitive intelligence tools that include–SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.
• The report covers the descriptive overview of catheter-related bloodstream infection, explaining its causes, signs and symptoms, pathogenesis and currently available therapies.
• Comprehensive insight has been provided into the catheter-related bloodstream infection epidemiology and treatment.
• Additionally, an all-inclusive account of both the current and emerging therapies for catheter-related bloodstream infection are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
• A detailed review of catheter-related bloodstream infection market; historical and forecasted is included in the report, covering the global drug outreach.
• The report provides an edge while developing business strategies, by understanding trends shaping and driving the global catheter-related bloodstream infection market
• In the coming years, catheter-related bloodstream infection market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies and academics are working to assess challenges and seek opportunities that could influence catheter-related bloodstream infection R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
• Major players are involved in developing therapies for catheter-related bloodstream infection. Launch of emerging therapies will significantly impact the catheter-related bloodstream infection market
• Our in-depth analysis of the pipeline assets across different stages of development (phase III and phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.
• Patient Population
• Therapeutic Approaches
• Catheter-Related Bloodstream Infection Pipeline Analysis
• Catheter-Related Bloodstream Infection Market Size and Trends
• Market Opportunities
• Impact of upcoming Therapies
• Nine Years Forecast
• Global Coverage
• Catheter-Related Bloodstream Infection Epidemiology Segmentation
• Key Cross Competition
• Highly Analyzed Market
• Drugs Uptake
• Current Treatment Practices
• Unmet Needs
• Pipeline Product Profiles
• Market Attractiveness
• Market Drivers and Barriers
Market Insights:
• What was the catheter-related bloodstream infection market share (%) distribution in 2017 and how it would look like in 2030?
• What would be the catheter-related bloodstream infection total market size as well as market size by therapies across the globe during the forecast period (2020–2030)?
• What are the key findings pertaining to the market across the globe and which country will have the largest catheter-related bloodstream infection market size during the forecast period (2020–2030)?
• At what CAGR, the catheter-related bloodstream infection market is expected to grow at the global level during the forecast period (2020–2030)?
• What would be the catheter-related bloodstream infection market outlook across the globe during the forecast period (2020–2030)?
• What would be the catheter-related bloodstream infection market growth till 2030 and what will be the resultant market size in the year 2030?
• How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?
Epidemiology Insights:
• What is the disease risk, burden and unmet needs of catheter-related bloodstream infection?
• What is the historical catheter-related bloodstream infection patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK), Japan, APAC (China, India, Taiwan, South Korea, and Australia), LATAM (Brazil, Mexico, Argentina, and Colombia), Middle East (Saudi Arabia and the United Arab Emirates), and Russia?
• What would be the forecasted patient pool of catheter-related bloodstream infection at the global level?
• What will be the growth opportunities across the globe concerning the patient population about catheter-related bloodstream infection?
• Out of the above-mentioned countries, which country would have the highest Incident population of catheter-related bloodstream infection during the forecast period (2020–2030)?
• At what CAGR the population is expected to grow across the globe during the forecast period (2020–2030)?
Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:
• What are the current options for the treatment of catheter-related bloodstream infection along with the approved therapy?
• What are the current treatment guidelines for the treatment of catheter-related bloodstream infection in the US and Spain?
• What is the catheter-related bloodstream infection marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, and efficacy, etc.?
• How many companies are developing therapies for the treatment of catheter-related bloodstream infection?
• How many therapies are developed by each company for the treatment of catheter-related bloodstream infection?
• How many emerging therapies are in the mid-stage and late stages of development for the treatment of catheter-related bloodstream infection?
• What are the key collaborations (Industry–Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the catheter-related bloodstream infection therapies?
• What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for catheter-related bloodstream infection and their status?
• What are the key designations that have been granted for the emerging therapies for catheter-related bloodstream infection?
• What are the global historical and forecasted market of catheter-related bloodstream infection?
What is Catheter-Related Bloodstream Infection?
Catheter-related bloodstream infection also known as catheter-related sepsis, defined as the presence of bacteremia originating from a catheter insertion. Antibiotics such as antibacterial and antifungal are used for the treatment of the disease
What was the market size of Catheter-Related Bloodstream Infection in 2017?
The market size for Catheter-Related Bloodstream Infection was found to be USD 694.7 million in 2017
How is epidemiology segmented for Catheter-Related Bloodstream Infection?
Total Incident Population of Catheter-Related Bloodstream Infection Total Diagnosed Incident Population of Catheter-Related Bloodstream Infection, and Diagnosed Incidence of Catheter-Related Bloodstream Infection by Causative Pathogens
Which drugs are involved in the Catheter-Related Bloodstream Infection market?
Neutrolin, Taurosept, Taurolock, IntraLock, Mino-Lok are involved in the Catheter-Related Bloodstream Infection market
Which companies are involved for Catheter-Related Bloodstream Infection market?
CorMedix, Geistlich Pharma, TauroPharm GmbH, Fresenius Medical Care, Citius Pharmaceuticals are involved for Catheter-Related Bloodstream Infection market
1. Key Insights
2. Catheter-Related Blood Stream Infection (CRBSI) Market Overview at a Glance
2.1. Total Market Share (%) Distribution of CRBSI in 2017
2.2. Total Market Share (%) Distribution of CRBSI in 2030
3. Catheter-Related Bloodstream Infection (CRBSI): Disease Background and Overview
3.1. Introduction
3.2. Difference between CLABSI and CRBSI
3.3. Causes of Catheter-Related Bloodstream Infection (CRBSI)
3.3.1. Micro-organisms
3.3.2. Intravascular Devices
3.4. Risk Factor Associated with Catheter-Related Bloodstream Infection (CRBSI)
3.5. Pathogenesis of Catheter-Related Bloodstream Infection (CRBSI)
3.6. Diagnosis of Catheter-Related Bloodstream Infection (CRBSI)
3.7. Diagnosis Guidelines Catheter-Related Bloodstream Infection (CRBSI)
3.7.1. Infectious Diseases Society of America (IDSA) Guidelines for CRBSI
3.7.2. Spanish Society of Infectious Diseases and Clinical Microbiology and (SEIMC) and the Spanish Society of Intensive and Critical Care Medicine and Coronary Units (SEMICYUC)
3.7.3. British Intestinal Failure Alliance (BIFA)
3.7.4. European Renal Best Practice (ERBP) Recommendations for Diagnosis of CRBSIs
4. Epidemiology and Patient Population
4.1.1. Key Findings
4.1.2. Total Incident Population of CRBSI in the Global Market
4.1.3. Total Diagnosed Incident Population of CRBSI in the Global Market
4.1.4. Some KOL Insights
5. United States Epidemiology
5.1. Assumptions and Rationale
5.2. Total Incident Population of CRBSI in the United States
5.3. Total Diagnosed Incident Population of CRBSI in the United States
5.4. Diagnosed Incidence of CRBSI by Causative Pathogens in the United States
6. EU5 Epidemiology
6.1. Germany Epidemiology
6.1.1. Assumptions and Rationale
6.1.2. Total Incident Population of CRBSI in Germany
6.1.3. Total Diagnosed Incident Population of CRBSI in Germany
6.1.4. Diagnosed Incidence of CRBSI by Causative Pathogens in Germany
6.2. France Epidemiology
6.2.1. Assumptions and rationale
6.2.2. Total Incident Population of CRBSI in France
6.2.3. Total Diagnosed Incident Population of CRBSI in France
6.2.4. Diagnosed Incidence of CRBSI by Causative Pathogens in France
6.3. Italy Epidemiology
6.3.1. Assumptions and Rationale
6.3.2. Total Incident Population of CRBSI in Italy
6.3.3. Total Diagnosed Incident Population of CRBSI in Italy
6.3.4. Diagnosed Incidence of CRBSI by Causative Pathogens in Italy
6.4. Spain Epidemiology
6.4.1. Assumptions and Rationale
6.4.2. Total Incident Population of CRBSI in Spain
6.4.3. Total Diagnosed Incident Population of CRBSI in Spain
6.4.4. Diagnosed Incidence of CRBSI by Causative Pathogens in Spain
6.5. United Kingdom Epidemiology
6.5.1. Assumptions and Rationale
6.5.2. Total Incident Population of CRBSI in the United Kingdom
6.5.3. Total Diagnosed Incident Population of CRBSI in the United Kingdom
6.5.4. Diagnosed Incidence of CRBSI by Causative Pathogens in the United Kingdom
7. APAC Epidemiology
7.1. Japan Epidemiology
7.1.1. Assumptions and Rationale
7.1.2. Total Incident Population of CRBSI in Japan
7.1.3. Total Diagnosed Incident Population of CRBSI in Japan
7.1.4. Diagnosed Incidence of CRBSI by Causative Pathogens in Japan
7.2. China Epidemiology
7.2.1. Assumptions and Rationale
7.2.2. Total Incident Population of CRBSI in China
7.2.3. Total Diagnosed Incident Population of CRBSI in China
7.2.4. Diagnosed Incidence of CRBSI by Causative Pathogens in China
7.3. India Epidemiology
7.3.1. Assumptions and Rationale
7.3.2. Total Incident Population of CRBSI in India
7.3.3. Total Diagnosed Incident Population of CRBSI in India
7.3.4. Diagnosed Incidence of CRBSI by Causative Pathogens in India
7.4. Taiwan Epidemiology
7.4.1. Assumptions and Rationale
7.4.2. Total Incident Population of CRBSI in Taiwan
7.4.3. Total Diagnosed Incident Population of CRBSI in Taiwan
7.4.4. Diagnosed Incidence of CRBSI by Causative Pathogens in Taiwan
7.5. South Korea Epidemiology
7.5.1. Assumptions and Rationale
7.5.2. Total Incident Population of CRBSI in South Korea
7.5.3. Total Diagnosed Incident Population of CRBSI in South Korea
7.5.4. Diagnosed Incidence of CRBSI by Causative Pathogens in South Korea
7.6. Australia Epidemiology
7.6.1. Assumptions and Rationale
7.6.2. Total Incident Population of CRBSI in Australia
7.6.3. Total Diagnosed Incident Population of CRBSI in Australia
7.6.4. Diagnosed Incidence of CRBSI by Causative Pathogens in Australia
8. LATAM Epidemiology
8.1. Argentina Epidemiology
8.1.1. Assumptions and Rationale
8.1.2. Total Incident Population of CRBSI in Argentina
8.1.3. Total Diagnosed Incident Population of CRBSI in Argentina
8.1.4. Diagnosed Incidence of CRBSI by Causative Pathogens in Argentina
8.2. Brazil Epidemiology
8.2.1. Assumptions and Rationale
8.2.2. Total Incident Population of CRBSI in Brazil
8.2.3. Total Diagnosed Incident Population of CRBSI in Brazil
8.2.4. Diagnosed Incidence of CRBSI by Causative Pathogens in Brazil
8.3. Mexico Epidemiology
8.3.1. Assumptions and Rationale
8.3.2. Total Incident Population of CRBSI in Mexico
8.3.3. Total Diagnosed Incident Population of CRBSI in Mexico
8.3.4. Diagnosed Incidence of CRBSI by Causative Pathogens in Mexico
8.4. Colombia Epidemiology
8.4.1. Assumptions and Rationale
8.4.2. Total Incident Population of CRBSI in Colombia
8.4.3. Total Diagnosed Incident Population of CRBSI in Colombia
8.4.4. Diagnosed Incidence of CRBSI by Causative Pathogens in Colombia
9. Middle East Epidemiology
9.1. Saudi Arabia Epidemiology
9.1.1. Assumptions and Rationale
9.1.2. Total Incident Population of CRBSI in Saudi Arabia
9.1.3. Total Diagnosed Incident Population of CRBSI in Saudi Arabia
9.1.4. Diagnosed Incidence of CRBSI by Causative Pathogens in Saudi Arabia
9.2. United Arab Emirates Epidemiology
9.2.1. Assumptions and Rationale
9.2.2. Total Incident Population of CRBSI in the United Arab Emirates
9.2.3. Total Diagnosed Incident Population of CRBSI in the United Arab Emirates
9.2.4. Diagnosed Incidence of CRBSI by Causative Pathogens in the United Arab Emirates
10. Russia Epidemiology
10.1.1. Assumptions and Rationale
10.1.2. Total Incident Population of CRBSI in Russia
10.1.3. Total Diagnosed Incident Population of CRBSI in Russia
10.1.4. Diagnosed Incidence of CRBSI by Causative Pathogens in Russia
11. Total Treatment Algorithm, Current Treatment, and Medical Practices
11.1. Treatment of Catheter-Related Bloodstream Infection (CRBSI)
11.1.1. General
11.1.2. Short-term Central Venous or Arterial CRBSI
11.1.3. Long-term Central Venous CRBSI
11.2. Treatment Guidelines for Catheter-related bloodstream infection (CRBSI)
11.2.1. Infectious Diseases Society of America: Guidelines for the pathogen-specific treatment
11.2.2. Spanish Society of Infectious Diseases: Treatment of CRBSIs
11.3. Prevention Guidelines of Catheter-Related Bloodstream Infection (CRBSI)
11.3.1. Infectious Diseases Society of America (IDSA), Healthcare Infection Control Practices Advisory Committee (HICPAC) of the Centers for Disease Control and Prevention (CDC):
11.3.2. European Renal Best Practice (ERBP) Recommendations for Prevention of CRBSIs
11.3.3. APSIC Guide for Prevention of Central Line-Associated Bloodstream Infection (CLABSI)
11.3.4. Indian Society of Intensive Care Medicine Guidelines for the Prevention of Vascular Catheter-Associated Infection
12. Unmet Needs
13. Marketed Products
13.1. Neutrolin: CorMedix
13.1.1. Product Description
13.1.2. Mechanism of Action
13.1.3. Regulatory milestones
13.1.4. Clinical Development
13.1.5. Clinical Trials Information
13.1.6. Safety and Efficacy
13.1.7. Product Profile
13.2. Taurosept: Geistlich Pharma
13.2.1. Product Description
13.2.2. Mechanism of Action
13.2.3. Regulatory milestones
13.2.4. Clinical Development
13.2.5. Safety and Efficacy
13.2.6. Product Profile
13.3. Taurolock: TauroPharm GmbH
13.3.1. Product Description
13.3.2. Mechanism of Action
13.3.3. Regulatory Milestones
13.3.4. Clinical Development
13.3.5. Clinical Trials Information
13.3.6. Safety and Efficacy
13.3.7. Product Profile
13.4. IntraLock: Fresenius Medical Care
13.4.1. Product Description
13.4.2. Mechanism of Action
13.4.3. Regulatory Milestones
13.4.4. Advantages
13.4.5. Product Profile
14. Off-label Drugs
14.1. Antibacterials
14.1.1. Daptomycin
14.1.1.1. Product Description
14.1.1.2. Mechanism of Action
14.1.1.3. Generic Availability
14.1.1.4. Clinical Trials Information
14.1.2. Vancomycin
14.1.2.1. Product Description
14.1.2.2. Mechanism of Action
14.1.2.3. Generic Availability
14.1.3. Cefazolin
14.1.3.1. Product Description
14.1.3.2. Mechanism of Action
14.1.3.3. Generic Availability
14.1.4. Ampicillin
14.1.4.1. Product Description
14.1.4.2. Mechanism of Action
14.1.4.3. Generic Availability
14.1.5. Ciprofloxacin
14.1.5.1. Product Description
14.1.5.2. Mechanism of Action
14.1.5.3. Generic Availability
14.1.6. Amikacin
14.1.6.1. Product Description
14.1.6.2. Mechanism of Action
14.1.6.3. Generic Availability
14.1.7. Teicoplanin
14.1.7.1. Product Description
14.1.7.2. Mechanism of Action
14.1.7.3. Generic Availability
14.2. Antifungals
14.2.1. Fluconazole
14.2.1.1. Product Description
14.2.1.2. Mechanism of Action
14.2.1.3. Generic Availability
14.2.2. Amphotericin B
14.2.2.1. Product Description
14.2.2.2. Mechanism of Action
14.2.2.3. Generic Availability
15. Emerging Therapies
15.1. Mino-Lok: Citius Pharmaceuticals
15.1.1. Product Description
15.1.2. Other Developmental Activities
15.1.3. Clinical Development
15.1.4. Product Profile
16. CRBSI: Global Market Analysis
16.1. Key Findings
16.1.1. Market Size of CRBSI in the Global Market
16.1.2. Market Size of CRBSI by Therapies in the Global Market
17. Total Market Size of North America
17.1. United States: Market Outlook
17.2. United States Market Size
17.2.1. Total Market size of CRBSI
17.2.2. Market Size of CRBSI by Therapies in the US
18. Total Market Size of Europe
18.1. EU-5 countries: Market Outlook
18.2. Germany Market Size
18.2.1. Total Market size of CRBSI
18.2.2. Market Size of CRBSI by therapies in Germany
18.3. France Market Size
18.3.1. Total Market size of CRBSI
18.3.2. Market Size of CRBSI by therapies in France
18.4. Italy Market Size
18.4.1. Total Market size of CRBSI
18.4.2. Market Size of CRBSI by therapies in Italy
18.5. Spain Market Size
18.5.1. Total Market size of CRBSI
18.5.2. Market Size of CRBSI by therapies in Spain
18.6. United Kingdom Market Size
18.6.1. Total Market size of CRBSI
18.6.2. Market Size of CRBSI by therapies in the UK
19. Total Market Size of APAC Countries
19.1. APAC Countries: Market Outlook
19.2. Japan Market Outlook
19.3. Japan Market Size
19.3.1. Total Market size of CRBSI
19.3.2. Market Size of CRBSI by therapies in Japan
19.4. China Market Size
19.4.1. Total Market size of CRBSI
19.4.2. Market Size of CRBSI by therapies in China
19.5. India Market Size
19.5.1. Total Market size of CRBSI
19.5.2. Market Size of CRBSI by therapies in India
19.6. Taiwan Market Size
19.6.1. Total Market size of CRBSI
19.6.2. Market Size of CRBSI by therapies in Taiwan
19.7. South Korea Market Size
19.7.1. Total Market size of CRBSI
19.7.2. Market Size of CRBSI by therapies in South Korea
19.8. Australia Market Size
19.8.1. Total Market size of CRBSI
19.8.2. Market Size of CRBSI by therapies in Australia
20. Total Market Size of LATAM Countries
20.1. LATAM Countries: Market Outlook
20.2. Argentina Market Size
20.2.1. Total Market size of CRBSI
20.2.2. Market Size of CRBSI by therapies in Argentina
20.3. Brazil Market Size
20.3.1. Total Market size of CRBSI
20.3.2. Market Size of CRBSI by therapies in Brazil
20.4. Mexico Market Size
20.4.1. Total Market size of CRBSI
20.4.2. Market Size of CRBSI by therapies in Mexico
20.5. Colombia Market Size
20.5.1. Total Market size of CRBSI
20.5.2. Market Size of CRBSI by therapies in Colombia
21. Russia: Market Outlook
21.1. Russia Market Size
21.1.1. Total Market size of CRBSI
21.1.2. Market Size of CRBSI by therapies in Russia
22. Total Market Size of Middle East Countries
22.1. Middle East Countries: Market Outlook
22.2. Saudi Arabia Market Size
22.2.1. Total Market size of CRBSI
22.2.2. Market Size of CRBSI by therapies in Saudi Arabia
22.3. UAE Market Size
22.3.1. Total Market size of CRBSI
22.3.2. Market Size of CRBSI by therapies in the UAE
23. Market Drivers
24. Market Barriers
25. Appendix
25.1. Report Methodology
26. DelveInsight Capabilities
27. Disclaimer
28. About DelveInsight
List of Tables:
Table 1 Terminology: CLABSI or CRBSI
Table 2 Various Risk Factors of CRBSIs
Table 3 Total Incident Population of CRBSI in the Global Market (2017–2030 )
Table 4 Total Diagnosed Incident Population of CRBSI in the Global Market (2017–2030 )
Table 5 Total Incident Population of CRBSI in the US (2017–2030)
Table 6 Total Diagnosed Incident Population of CRBSI in the US (2017–2030)
Table 7 Diagnosed Incidence of CRBSI by Causative Pathogens in the US (2017–2030)
Table 8 Total Incident Population of CRBSI in Germany (2017–2030)
Table 9 Total Diagnosed Incident Population of CRBSI in Germany (2017–2030)
Table 10 Diagnosed Incidence of CRBSI by Causative Pathogens in Germany (2017–2030)
Table 11 Total Incident Population of CRBSI in France (2017–2030)
Table 12 Total Diagnosed Incident Population of CRBSI in France (2017–2030)
Table 13 Diagnosed Incidence of CRBSI by Causative Pathogens in France (2017–2030)
Table 14 Total Incident Population of CRBSI in Italy (2017–2030)
Table 15 Total Diagnosed Incident Population of CRBSI in Italy (2017–2030)
Table 16 Diagnosed Incidence of CRBSI by Causative Pathogens in Italy (2017–2030 )
Table 17 Total Incident Population of CRBSI in Spain (2017–2030)
Table 18 Total Diagnosed Incident Population of CRBSI in Spain (2017–2030)
Table 19 Diagnosed Incidence of CRBSI by Causative Pathogens in Spain (2017–2030)
Table 20 Total Incident Population of CRBSI in the UK (2017–2030)
Table 21 Total Diagnosed Incident Population of CRBSI in the UK (2017–2030 )
Table 22 Diagnosed Incidence of CRBSI by Causative Pathogens in the UK (2017–2030)
Table 23 Total Incident Population of CRBSI in Japan (2017–2030)
Table 24 Total Diagnosed Incident Population of CRBSI in Japan (2017–2030)
Table 25 Diagnosed Incidence of CRBSI by Causative Pathogens in Japan (2017–2030)
Table 26 Total Incident Population of CRBSI in China (2017–2030)
Table 27 Total Diagnosed Incident Population of CRBSI in China (2017–2030)
Table 28 Diagnosed Incidence of CRBSI by Causative Pathogens in China (2017–2030)
Table 29 Total Incident Population of CRBSI in India (2017–2030)
Table 30 Total Diagnosed Incident Population of CRBSI in India (2017–2030 )
Table 31 Diagnosed Incidence of CRBSI by Causative Pathogens in India (2017–2030)
Table 32 Total Incident Population of CRBSI in Taiwan (2017–2030)
Table 33 Total Diagnosed Incident Population of CRBSI in Taiwan (2017–2030)
Table 34 Diagnosed Incidence of CRBSI by Causative Pathogens in Taiwan (2017–2030)
Table 35 Total Incident Population of CRBSI in South Korea (2017–2030)
Table 36 Total Diagnosed Incident Population of CRBSI in South Korea (2017–2030)
Table 37 Diagnosed Incidence of CRBSI by Causative Pathogens in South Korea (2017–2030)
Table 38 Total Incident Population of CRBSI in Australia (2017–2030)
Table 39 Total Diagnosed Incident Population of CRBSI in Australia (2017–2030)
Table 40 Diagnosed Incidence of CRBSI by Causative Pathogens in Australia (2017–2030)
Table 41 Total Incident Population of CRBSI in Argentina (2017–2030)
Table 42 Total Diagnosed Incident Population of CRBSI in Argentina (2017–2030)
Table 43 Diagnosed Incidence of CRBSI by Causative Pathogens in Argentina (2017–2030)
Table 44 Total Incident Population of CRBSI in Brazil (2017–2030)
Table 45 Total Diagnosed Incident Population of CRBSI in Brazil (2017–2030)
Table 46 Diagnosed Incidence of CRBSI by Causative Pathogens in Brazil (2017–2030)
Table 47 Total Incident Population of CRBSI in Mexico (2017–2030)
Table 48 Total Diagnosed Incident Population of CRBSI in Mexico (2017–2030)
Table 49 Diagnosed Incidence of CRBSI by Causative Pathogens in Mexico (2017–2030)
Table 50 Total Incident Population of CRBSI in Colombia (2017–2030)
Table 51 Total Diagnosed Incident Population of CRBSI in Colombia (2017–2030)
Table 52 Diagnosed Incidence of CRBSI by Causative Pathogens in Colombia (2017–2030)
Table 53 Total Incident Population of CRBSI in Saudi Arabia (2017–2030)
Table 54 Total Diagnosed Incident Population of CRBSI in Saudi Arabia (2017–2030)
Table 55 Diagnosed Incidence of CRBSI by Causative Pathogens in Saudi Arabia (2017–2030)
Table 56 Total Incident Population of CRBSI in the United Arab Emirates (2017–2030)
Table 57 Total Diagnosed Incident Population of CRBSI in the United Arab Emirates (2017–2030)
Table 58 Diagnosed Incidence of CRBSI by Causative Pathogens in the United Arab Emirates (2017–2030)
Table 59 Total Incident Population of CRBSI in Russia (2017–2030)
Table 60 Total Diagnosed Incident Population of CRBSI in Russia (2017–2030)
Table 61 Diagnosed Incidence of CRBSI by Causative Pathogens in Russia (2017–2030)
Table 62 The Main Antimicrobial Drug and Dosage Regimens that should be used for Catheter-related Infection.
Table 63 Categories for the strength of each recommendation
Table 64 Categories for quality of evidence on which recommendations are made
Table 65 Neutrolin (CRMD003), Clinical Trial Description, 2020
Table 66 Taurosept, Clinical Trial Description, 2020
Table 67 TauroLock, Clinical Trial Description, 2020
Table 68 Generic Products of Daptomycin in the Global Market
Table 69 Daptomycin, Clinical Trial Description, 2020
Table 70 Generic Products of Vancomycin in the Global Market
Table 71 Generic Products of Cefazolin in the Global Market
Table 72 Generic Products of Ampicillin in the Global Market
Table 73 Generic Products of Ciprofloxacin available in the Global Market
Table 74 Generic Products of Amikacin in the Global Market
Table 75 Generic Products of Teicoplanin in the Global Market
Table 76 Generic Products of Fluconazole in the Global Market
Table 77 Generic Products of Amphotericin B in the Global Market
Table 78 Mino-Lok, Clinical Trial Description, 2020
Table 79 Market Size of CRBSI in the Global Market in USD Million (2017–2030 )
Table 80 Market Size of CRBSI by therapies in the Global Market, in USD Million (2017–2030)
Table 81 Market Size of CRBSI in North America in USD Million (2017–2030 )
Table 82 The US Market Size of CRBSI in USD Million (2017–2030)
Table 83 Market Size of CRBSI by therapies in the United States, in USD Million (2017–2030)
Table 84 Market Size of CRBSI in Europe in USD Million (2017–2030)
Table 85 Germany Market Size of CRBSI in USD Million (2017–2030)
Table 86 Market Size of CRBSI by therapies in Germany, in USD Million (2017–2030)
Table 87 France Market Size of CRBSI in USD Million (2017–2030)
Table 88 Market Size of CRBSI by therapies in France, in USD Million (2017–2030)
Table 89 Italy Market Size of CRBSI in USD Million (2017–2030)
Table 90 Market Size of CRBSI by therapies in Italy, in USD Million (2017–2030)
Table 91 Spain Market Size of CRBSI in USD Million (2017–2030)
Table 92 Market Size of CRBSI by therapies in Spain, in USD Million (2017–2030)
Table 93 The UK Market Size of CRBSI in USD Million (2017–2030)
Table 94 Market Size of CRBSI by therapies in the UK, in USD Million (2017–2030)
Table 95 Market Size of CRBSI in APAC in USD Million (2017–2030)
Table 96 Japan Market Size of CRBSI in USD Million (2017–2030)
Table 97 Market Size of CRBSI by therapies in the Japan, in USD Million (2017–2030)
Table 98 Germany Market Size of CRBSI in USD Million (2017–2030)
Table 99 Market Size of CRBSI by therapies in China, in USD Million (2017–2030 )
Table 100 India Market Size of CRBSI in USD Million (2017–2030)
Table 101 Market Size of CRBSI by therapies in India, in USD Million (2017–2030)
Table 102 Taiwan Market Size of CRBSI in USD Million (2017–2030)
Table 103 Market Size of CRBSI by therapies in Taiwan, in USD Million (2017–2030)
Table 104 South Korea Market Size of CRBSI in USD Million (2017–2030)
Table 105 Market Size of CRBSI by therapies in South Korea, in USD Million (2017–2030)
Table 106 Australia Market Size of Australia in USD Million (2017–2030)
Table 107 Market Size of CRBSI by therapies in Australia, in USD Million (2017–2030)
Table 108 Market Size of CRBSI in LATAM Countries in USD Million (2017–2030)
Table 109 Argentina Market Size of CRBSI in USD Million (2017–2030)
Table 110 Market Size of CRBSI by therapies in Argentina, in USD Million (2017–2030)
Table 111 Brazil Market Size of CRBSI in USD Million (2017–2030)
Table 112 Market Size of CRBSI by therapies in Brazil, in USD Million (2017–2030)
Table 113 Mexico Market Size of CRBSI in USD Million (2017–2030)
Table 114 Market Size of CRBSI by therapies in Mexico, in USD Million (2017–2030 )
Table 115 Colombia Market Size of CRBSI in USD Million (2017–2030)
Table 116 Market Size of CRBSI by therapies in Colombia, in USD Million (2017–2030)
Table 117 Market Size of Russia by therapies in USD Million (2017–2030 )
Table 118 Market Size of CRBSI by therapies in Russia, in USD Million (2017–2030)
Table 119 Market Size of CRBSI in MENA Region in USD Million (2017–2030 )
Table 120 Saudi Arabia Market Size of CRBSI in USD Million (2017–2030)
Table 121 Market Size of CRBSI by therapies in Saudi Arabia, in USD Million (2017–2030)
Table 122 UAE Market Size of CRBSI in USD Million (2017–2030)
Table 123 Market Size of CRBSI by therapies in the UAE, in USD Million (2017–2030)
List of Figures:
Figure 1 Types of Central Venous and Arterial Catheter and their sites of insertion
Figure 2 Important pathogenic determinants of catheter-related Infection
Figure 3 Potential sources of infection of a percutaneous intravascular device
Figure 4 Total Incident Population of CRBSI in the Global Market (2017–2030)
Figure 5 Total Diagnosed Incident Population of CRBSI in the Global Market (2017–2030)
Figure 6 Total Incident Population of CRBSI in the US (2017–2030)
Figure 7 Total Diagnosed Incident Population of CRBSI in the US (2017–2030)
Figure 8 Diagnosed Incidence of CRBSI by Causative Pathogens in the US (2017–2030)
Figure 9 Total Incident Population of CRBSI in Germany (2017–2030)
Figure 10 Total Diagnosed Incident Population of CRBSI in Germany (2017–2030)
Figure 11 Diagnosed Incidence of CRBSI by Causative Pathogens in Germany (2017–2030)
Figure 12 Total Incident Population of CRBSI in France (2017–2030)
Figure 13 Total Diagnosed Incident Population of CRBSI in France (2017–2030)
Figure 14 Diagnosed Incidence of CRBSI by Causative Pathogens in France (2017–2030)
Figure 15 Total Incident Population of CRBSI in Italy (2017–2030)
Figure 16 Total Diagnosed Incident Population of CRBSI in Italy (2017–2030)
Figure 17 Diagnosed Incidence of CRBSI by Causative Pathogens in Italy (2017–2030)
Figure 18 Total Incident Population of CRBSI in Spain (2017–2030)
Figure 19 Total Diagnosed Incident Population of CRBSI in Spain (2017–2030)
Figure 20 Diagnosed Incidence of CRBSI by Causative Pathogens in Spain (2017–2030)
Figure 21 Total Incident Population of CRBSI in the United Kingdom (2017–2030)
Figure 22 Total Diagnosed Incident Population of CRBSI in the United Kingdom (2017–2030)
Figure 23 Diagnosed Incidence of CRBSI by Causative Pathogens in the United Kingdom (2017–2030)
Figure 24 Total Incident Population of CRBSI in Japan (2017–2030)
Figure 25 Total Diagnosed Incident Population of CRBSI in Japan (2017–2030)
Figure 26 Diagnosed Incidence of CRBSI by Causative Pathogens in Japan (2017–2030)
Figure 27 Total Incident Population of CRBSI in China (2017–2030)
Figure 28 Total Diagnosed Incident Population of CRBSI in China (2017–2030)
Figure 29 Diagnosed Incidence of CRBSI by Causative Pathogens in China (2017–2030)
Figure 30 Total Incident Population of CRBSI in India (2017–2030)
Figure 31 Total Diagnosed Incident Population of CRBSI in India (2017–2030)
Figure 32 Diagnosed Incidence of CRBSI by Causative Pathogens in India (2017–2030)
Figure 33 Total Incident Population of CRBSI in Taiwan (2017–2030)
Figure 34 Total Diagnosed Incident Population of CRBSI in Taiwan (2017–2030)
Figure 35 Diagnosed Incidence of CRBSI by Causative Pathogens in Taiwan (2017–2030)
Figure 36 Total Incident Population of CRBSI in South Korea (2017–2030)
Figure 37 Total Diagnosed Incident Population of CRBSI in South Korea (2017–2030)
Figure 38 Diagnosed Incidence of CRBSI by Causative Pathogens in South Korea (2017–2030)
Figure 39 Total Incident Population of CRBSI in Australia (2017–2030)
Figure 40 Total Diagnosed Incident Population of CRBSI in Australia (2017–2030)
Figure 41 Diagnosed Incidence of CRBSI by Causative Pathogens in Australia (2017–2030)
Figure 42 Total Incident Population of CRBSI in Argentina (2017–2030)
Figure 43 Total Diagnosed Incident Population of CRBSI in Argentina (2017–2030)
Figure 44 Diagnosed Incidence of CRBSI by Causative Pathogens in Argentina (2017–2030)
Figure 45 Total Incident Population of CRBSI in Brazil (2017–2030)
Figure 46 Total Diagnosed Incident Population of CRBSI in Brazil (2017–2030)
Figure 47 Diagnosed Incidence of CRBSI by Causative Pathogens in Brazil (2017–2030)
Figure 48 Total Incident Population of CRBSI in Mexico (2017–2030)
Figure 49 Total Diagnosed Incident Population of CRBSI in Mexico (2017–2030)
Figure 50 Diagnosed Incidence of CRBSI by Causative Pathogens in Mexico (2017–2030)
Figure 51 Total Incident Population of CRBSI in Colombia (2017–2030)
Figure 52 Total Diagnosed Incident Population of CRBSI in Colombia (2017–2030)
Figure 53 Diagnosed Incidence of CRBSI by Causative Pathogens in Colombia (2017–2030)
Figure 54 Total Incident Population of CRBSI in Saudi Arabia (2017–2030)
Figure 55 Total Diagnosed Incident Population of CRBSI in Saudi Arabia (2017–2030)
Figure 56 Diagnosed Incidence of CRBSI by Causative Pathogens in Saudi Arabia (2017–2030)
Figure 57 Total Incident Population of CRBSI in the United Arab Emirates (2017–2030)
Figure 58 Total Diagnosed Incident Population of CRBSI in the United Arab Emirates (2017–2030)
Figure 59 Diagnosed Incidence of CRBSI by Causative Pathogens in the United Arab Emirates (2017–2030)
Figure 60 Total Incident Population of CRBSI in Russia (2017–2030)
Figure 61 Total Diagnosed Incident Population of CRBSI in Russia (2017–2030)
Figure 62 Diagnosed Incidence of CRBSI by Causative Pathogens in Russia (2017–2030)
Figure 63 Flow chart Summarizing Approaches for Systemic Antibiotic Treatment.
Figure 64 Approach to the management of patients with short-term central venous catheter-related or arterial catheter-related bloodstream infection. CFU, colony-forming units; S. aureus, Staphylococcus aureus.
Figure 65 Approach to the treatment of a patient with a long-term central venous catheter (CVC)
or a port (P)-related bloodstream infection.
Figure 66 Approach to the treatment of a patient with confirmed CRBSI.
Figure 67 Unmet Needs
Figure 68 Market Size of CRBSI in the Global Market in USD Million (2017–2030)
Figure 69 Market Size of CRBSI by therapies in the Global Market, in USD Million (2017–2030)
Figure 70 Market Size of CRBSI in North America in USD Million (2017–2030)
Figure 71 Market Size of CRBSI in the US, USD Millions (2017–2030)
Figure 72 Market Size of CRBSI by therapies in the United States, in USD Million (2017–2030)
Figure 73 Market Size of CRBSI in Europe in USD Million (2017–2030)
Figure 74 Market Size of CRBSI in Germany, USD Millions (2017–2030)
Figure 75 Market Size of CRBSI by therapies in Germany, in USD Million (2017–2030)
Figure 76 Market Size of CRBSI in France, USD Millions (2017–2030)
Figure 77 Market Size CRBSI by therapies in France, in USD Million (2017–2030)
Figure 78 Market Size of CRBSI in Italy, USD Millions (2017–2030)
Figure 79 Market Size of CRBSI by therapies in Italy in USD Million (2017–2030)
Figure 80 Market Size of CRBSI in Spain, USD Millions (2017–2030)
Figure 81 Market Size of CRBSI by therapies in Spain in USD Million (2017–2030)
Figure 82 Market Size of CRBSI in the UK, USD Millions (2017–2030)
Figure 83 Market Size of CRBSI by therapies in the UK in USD Million (2017–2030)
Figure 84 Market Size of CRBSI in APAC in USD Million (2017–2030)
Figure 85 Market Size of CRBSI in Japan, USD Millions (2017–2030)
Figure 86 Market Size of CRBSI by therapies in Japan in USD Million (2017–2030)
Figure 87 Market Size of CRBSI in China, USD Millions (2017–2030)
Figure 88 Market Size of CRBSI by therapies in China, in USD Million (2017–2030)
Figure 89 Market Size of CRBSI in India, USD Millions (2017–2030)
Figure 90 Market Size CRBSI by therapies in India, in USD Million (2017–2030)
Figure 91 Market Size of CRBSI in Taiwan, USD Millions (2017–2030)
Figure 92 Market Size of CRBSI by therapies in Taiwan in USD Million (2017–2030)
Figure 93 Market Size of CRBSI in South Korea, USD Millions (2017–2030)
Figure 94 Market Size of CRBSI by therapies in South Korea in USD Million (2017–2030)
Figure 95 Market Size of CRBSI in Australia, USD Millions (2017–2030)
Figure 96 Market Size of CRBSI by therapies in Australia in USD Million (2017–2030)
Figure 97 Market Size of CRBSI in LATAM Countries in USD Million (2017–2030)
Figure 98 Market Size of CRBSI in Argentina, USD Millions (2017–2030)
Figure 99 Market Size of CRBSI by therapies in Argentina, in USD Million (2017–2030)
Figure 100 Market Size of CRBSI in Brazil, USD Millions (2017–2030)
Figure 101 Market Size CRBSI by therapies in Brazil, in USD Million (2017–2030)
Figure 102 Market Size of CRBSI in Mexico, USD Millions (2017–2030)
Figure 103 Market Size of CRBSI by therapies in Mexico in USD Million (2017–2030)
Figure 104 Market Size of CRBSI in Colombia, USD Millions (2017–2030)
Figure 105 Market Size of CRBSI by therapies in Colombia in USD Million (2017–2030)
Figure 106 Market Size of CRBSI in Russia, USD Millions (2017–2030)
Figure 107 Market Size of CRBSI by therapies in Russia in USD Million (2017–2030)
Figure 108 Market Size of CRBSI in MENA Region in USD Million (2017–2030)
Figure 109 Market Size of CRBSI in Saudi Arabia, USD Millions (2017–2030)
Figure 110 Market Size of CRBSI by therapies in Saudi Arabia, in USD Million (2017–2030)
Figure 111 Market Size of CRBSI in UAE, USD Millions (2017–2030)
Figure 112 Market Size CRBSI by therapies in the UAE, in USD Million (2017–2030)
Figure 113 Market Drivers
Figure 114 Market Barriers
